HACKENSACK, N.J., (October 10, 2011) — John Theurer Cancer Center at Hackensack University Medical Center, one of nation’s top 50 best hospitals for cancer, will host the New Frontiers in the Management of Solid and Liquid Tumors on November 3-4 from 7:00am to 4:00pm. This complimentary Continuing Medical Education (CME) program will feature internationally recognized oncologists and hematologists who will provide the latest updates on state-of the-art treatment modalities including novel therapies and new prognostic models in hematological and solid tumors.

“The oncology treatment landscape is rapidly changing,” Andre Goy, M.D., M.S., Chairman and Director and Chief of Lymphoma, John Theurer Cancer Center and the program Chair. “This program has been designed to help physicians gain additional insight into how translational research can be applied to the clinic for improved patient outcomes.”

Key topics include emerging best practices and ongoing studies in hematological malignancies and solid tumors, the impact of novel therapies in the care of hematology-oncology and solid tumor patients, new modalities in imaging and its best use in cancer patients, biomarkers and new prognostic markers in lymphomas and leukemias, the impact of emerging molecular markers in solid tumors, and the shifting paradigms in the treatment of multiple myeloma. A 15-minute Q&A will follow all presentations.

“This is a great opportunity for physicians and healthcare professionals to hear about the newest research from leading oncology and hematology physicians,” Stuart L. Goldberg, M.D., Chief, Leukemia, John Theurer Cancer Center and program Co-Chair. “We are fortunate to have some of the worlds’ foremost experts in solid and liquid tumors present information that will guide the development of future therapies.”

Featured Speakers and Topics for Thursday, November 3:

• Volker Diehl, M.D., Professor, University of Cologne, Germany
  Customization: The Treatment of Hodgkin’s Disease
• Jean-Luc Harousseau, M.D., Professor of Hematology, Head, Dept. of Clinical Hematology, Director of the Cancer Center Rene Gauducheau, University of Nantes, France Impact of Novel Therapies in the Management of Multiple Myeloma
• Richard Champlin, M.D., Chair, Dept. of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The Univ. of Texas MD Anderson Cancer Center
  Newest Modalities in Bone Marrow Transplantation
• Thomas Habermann, M.D., Professor of Medicine, Division of Hematology, Mayo Clinic
  Treatment of Large-Cell Lymphoma
• Susan O’Brien, M.D., Professor, Dept. of Leukemia, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center
  Newest Strategies in the Treatment of CML/CLL
• Myron Czuczman, M.D., Professor Chief, Lymphoma/Myeloma Service, Dept. of Medicine Head, Lymphoma Translational Research Laboratory Dept. of Immunology Roswell Park Cancer Center
  Evolving Management of Follicular Lymphoma

Featured Speakers and Topics for Friday, November 4:

• Shiladitya Sengupta, M.D., Assistant Professor of Medicine and Health Sciences and Technology, Harvard Medical School, Brigham & Women’s Hospital
  Personalized Medicine Approaches in Oncology
• Christoper Logothetis, M.D., Dept. Chair, Dept. of Genitourinary Medical Oncology, Division of Cancer Medicine, the Univ. of Texas MD Anderson Cancer Center
  Current Landscapes in the Management of Prostate Cancer
• Christopher Azzoli, M.D., Assistant Member, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center
  Current Modalities in the Treatment of Lung Cancer
• Axel Grothey, M.D., Professor of Oncology; Consultant, Medical Oncology, Mayo Clinic
  New Perspectives in GI Malignancies
• Kevin R. Fox, M.D., Director, Rena Rowan Breast Center, Perelman Center for Advanced Medicine at Penn Medicine
  Newest Approach to Breast Cancer
• Steven Horwitz, M.D., Assistant Attending, Lymphoma Service, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center
  Managing T-Cell Lymphoma

“We are committed to providing physicians and healthcare providers with the best educational programs to help clinicians manage today’s most complicated cases in cancer,” said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer and Professor and Vice President of Cancer Services, John Theurer Cancer Center. “I would like to thank Dr. Goy for spearheading this important conference and the impressive panel of experts for presenting at the John Theurer Cancer Center.”

Registration, breakfast and lunch are complimentary. This CME conference is primarily for physicians, medical oncologists, hematologists, nurses and other healthcare professionals involved in the care of oncology patients.

Hackensack University Medical Center is accredited by the Medical Society of New Jersey to sponsor continuing medical education for physicians. This particular educational activity has been designated for 12.0 AMA PRA Category 1 Credit(s), based on the extent of each physicians’ participation in the activity.

The conference will be held at John Theurer Cancer Center, 92 Second Street, Hackensack, NJ in the George and June Croonquist Conference Center on the first floor. For more information and to register, please visit jtcancercenter.org/CMEConference and download brochure.

About John Theurer Cancer Center at Hackensack University Medical Center
John Theurer Cancer Center at Hackensack University Medical Center is among the nation’s top 50 U.S. News and World Report Best Hospitals for cancer – the only Cancer Center in New Jersey with this prestigious designation. The 14 specialized divisions cover the complete spectrum of cancer care with a specialized team of medical, surgical, research, nursing, and support staff.

Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. In January 2011, the John Theurer Cancer Center began providing care in a new 155,000-square-foot building that enhances the Cancer Center’s ability to deliver multidisciplinary extraordinary care, best-in-class clinical quality, and cutting-edge research. For more information please go to jtcancercenter.org.


Media Contact: Amy Leahing, Phone: 305.458.0599, Email: amy.leahing@zibbel.com